I/O play­er iTeos lines up a $75M round as it preps for hu­man stud­ies, plans a leap to US hub

The Bel­gian biotech iTeos is find­ing out just how gen­er­ous in­vestors can be when it comes to back­ing a new drug that might play a key as­sist with the first-gen­er­a­tion of im­muno-on­col­o­gy drugs on the mar­ket. The group has hauled in a $75 mil­lion round de­signed to get its lead drug — an adeno­sine A2A an­tag­o­nist — in­to the clin­ic lat­er this year.

The mon­ey will al­so fund a move in­to Cam­bridge, MA as the biotech builds out its top team in the US in prepa­ra­tion for an IPO at some point.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.